Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription 28.06.2021 1 AJR Am J Roentgenol 3 Am J Clin Oncol 1 Am J Clin Pathol 2 Ann Surg Oncol 1 Anticancer Res 2 BMC Cancer 2 Br J Cancer 10 Breast Cancer 1 Breast Cancer (Auckl) 2 Breast Cancer (Dove Med Press) 65 Breast Cancer Res Treat 3 Breast J 5 Cancer 1 Cancer Cell 1 Cancer Chemother Pharmacol 1 Cancer Lett 4 Cancer Res 7 Clin Breast Cancer 2 Eur J Cancer 6 Eur Radiol 1 Exp Cell Res 2 Int J Cancer 1 Int J Radiat Oncol Biol Phys 3 J Natl Cancer Inst 1 J Surg Oncol 1 Lancet Oncol 3 NPJ Breast Cancer 1 Oncogene 1 Oncology (Williston Park) 2 PLoS Comput Biol 6 PLoS One 2 Pol J Radiol 1 Proc Natl Acad Sci U S A 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. HEINE J, Fowler E, Scott CG, Jensen MR, et al
   Mammographic Variation Measures, Breast Density, and Breast Cancer Risk.
   AJR Am J Roentgenol. 2021 Jun 23:1-10. doi: 10.2214/AJR.20.22794.
   PubMed         Abstract available
   
   

   
   Am J Clin Oncol

2. MELHEM J, Amarin M, Odeh G, Al-Bustami N, et al
   Intercostobrachial Nerve (ICBN) Preservation Versus Sacrifice in Axillary Dissection: Randomized Controlled Trial.
   Am J Clin Oncol. 2021;44:206-209.
   PubMed         Abstract available
   
   
3. HIRKO KA, Regan MM, Remolano MC, Schlossman J, et al
   Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer.
   Am J Clin Oncol. 2021 Jun 21. pii: 00000421-900000000-98550.
   PubMed         Abstract available
   
   
4. SUSSELL J, Singh Jhuti G, Antao V, Herrera-Restrepo O, et al
   Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States.
   Am J Clin Oncol. 2021;44:340-349.
   PubMed         Abstract available
   
   

   
   Am J Clin Pathol

5. ASIRVATHAM JR, Jorns JM
   How Do Pathologists in Academic Institutions Across the United States and Canada Evaluate Sentinel Lymph Nodes in Breast Cancer?
   Am J Clin Pathol. 2021 Jun 24. pii: 6308671. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

6. SROUR MK, Tseng J, Chung A, Giuliano AE, et al
   Contemporary Cancer Program Practice Profile Report (CP3R) Compliance Rates for Breast Cancer: A National Cancer Database Analysis.
   Ann Surg Oncol. 2021 Jun 16. pii: 10.1245/s10434-021-10028.
   PubMed         Abstract available
   
   
7. MYERS SP, Ahrendt GM, Lee JS, Steiman JG, et al
   Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer.
   Ann Surg Oncol. 2021 Jun 17. pii: 10.1245/s10434-021-10195.
   PubMed         Abstract available
   
   

   
   Anticancer Res

8. OHLINGER R, Alwafai Z, Paepke S, Zygmunt M, et al
   Patient Quality of Life After Subpectoral Implant-based Breast Reconstruction With Synthetic or Biological Materials.
   Anticancer Res. 2021;41:3075-3082.
   PubMed         Abstract available
   
   

   
   BMC Cancer

9. GUO L, Xie G, Wang R, Yang L, et al
   Local treatment for triple-negative breast cancer patients undergoing chemotherapy: breast-conserving surgery or total mastectomy?
   BMC Cancer. 2021;21:717.
   PubMed         Abstract available
   
   
10. HALLER H, Voiss P, Cramer H, Paul A, et al
    The INTREST registry: protocol of a multicenter prospective cohort study of predictors of women's response to integrative breast cancer treatment.
    BMC Cancer. 2021;21:724.
    PubMed         Abstract available
    
    

    
    Br J Cancer

11. DAVE RV, Kim B, Courtney A, O'Connell R, et al
    Publisher Correction: Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C study.
    Br J Cancer. 2021 Jun 23. pii: 10.1038/s41416-021-01465.
    PubMed        
    
    
12. BURRIS HA, Chan A, Bardia A, Thaddeus Beck J, et al
    Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
    Br J Cancer. 2021 Jun 22. pii: 10.1038/s41416-021-01415.
    PubMed         Abstract available
    
    

    
    Breast Cancer

13. YAGHOUBI S, Gharibi T, Karimi MH, Sadeqi Nezhad M, et al
    Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
    Breast Cancer. 2021;28:216-225.
    PubMed         Abstract available
    
    
14. MICHA AE, Sinnett V, Downey K, Allen S, et al
    Patient and clinician satisfaction and clinical outcomes of Magseed compared with wire-guided localisation for impalpable breast lesions.
    Breast Cancer. 2021;28:196-205.
    PubMed         Abstract available
    
    
15. JOSHI A, Larkins S, Evans R, Moodley N, et al
    Use and impact of breast cancer survivorship care plans: a systematic review.
    Breast Cancer. 2021 Jun 19. pii: 10.1007/s12282-021-01267.
    PubMed         Abstract available
    
    
16. PARKS RM, Alfarsi LH, Green AR, Cheung KL, et al
    Biology of primary breast cancer in older women beyond routine biomarkers.
    Breast Cancer. 2021 Jun 24. pii: 10.1007/s12282-021-01266.
    PubMed         Abstract available
    
    
17. SECOMBE KR, Ball IA, Shirren J, Wignall AD, et al
    Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant.
    Breast Cancer. 2021;28:99-109.
    PubMed         Abstract available
    
    
18. WEI Y, Li H, Qu Q
    miR-484 suppresses endocrine therapy-resistant cells by inhibiting KLF4-induced cancer stem cells in estrogen receptor-positive cancers.
    Breast Cancer. 2021;28:175-186.
    PubMed         Abstract available
    
    
19. ZHAO H
    The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
    Breast Cancer. 2021;28:187-195.
    PubMed         Abstract available
    
    
20. BOLAND MR, Nugent T, Nolan J, O'Mahony J, et al
    Fibromatosis of the breast: a 10-year multi-institutional experience and review of the literature.
    Breast Cancer. 2021;28:168-174.
    PubMed         Abstract available
    
    
21. ZHAO W, Tian Q, Zhao A, Wang B, et al
    The role of adjuvant radiotherapy in patients with malignant phyllodes tumor of the breast: a propensity-score matching analysis.
    Breast Cancer. 2021;28:110-118.
    PubMed         Abstract available
    
    
22. NAHVIJOU A, Safari H, Yousefi M, Rajabi M, et al
    Mapping the cancer-specific FACT-B onto the generic SF-6Dv2.
    Breast Cancer. 2021;28:130-136.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Auckl)

23. ARAFAH MA, Ouban A, Ameer OZ, Quek KJ, et al
    KI-67 LI Expression in Triple-Negative Breast Cancer Patients and Its Significance.
    Breast Cancer (Auckl). 2021;15:11782234211016977.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

24. JAGOSKY M, Tan AR
    Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data.
    Breast Cancer (Dove Med Press). 2021;13:393-407.
    PubMed         Abstract available
    
    
25. WAKO Z, Mengistu D, Dinegde NG, Asefa T, et al
    Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer Attending the Tikur Anbessa Specialized Hospital, Addis Ababa Ethiopia, 2019: A Cross-sectional Study.
    Breast Cancer (Dove Med Press). 2021;13:383-392.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

26. LACOUTURE ME, Dion H, Ravipaty S, Jimenez JJ, et al
    A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia.
    Breast Cancer Res Treat. 2021;186:107-114.
    PubMed         Abstract available
    
    
27. MESSORI A, Bartoli L, Ferracane E
    Implant-based breast reconstruction: re-analysis of the odds ratio for skin flap necrosis.
    Breast Cancer Res Treat. 2021;185:887.
    PubMed        
    
    
28. PARKS RM, Albanghali MA, Syed BM, Green AR, et al
    Patterns of biomarker expression in patients treated with primary endocrine therapy - a unique insight using core needle biopsy tissue microarray.
    Breast Cancer Res Treat. 2021;185:647-655.
    PubMed         Abstract available
    
    
29. KOPANS DB
    The wisdom trial is based on faulty reasoning and has major design and execution problems.
    Breast Cancer Res Treat. 2021;185:549-556.
    PubMed         Abstract available
    
    
30. KELLY BN, Kantor O, Tang R, Coopey SB, et al
    Similar rates of residual disease in patients with DCIS within 2 mm of lumpectomy margin regardless of the presence of invasive carcinoma.
    Breast Cancer Res Treat. 2021;186:807-814.
    PubMed         Abstract available
    
    
31. OHNO S, Saji S, Masuda N, Tsuda H, et al
    Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N.SAS-BC 01 trial and CUBC trial).
    Breast Cancer Res Treat. 2021;186:135-147.
    PubMed         Abstract available
    
    
32. LUITEN JD, Luiten EJT, van der Sangen MJC, Vreuls W, et al
    Patterns of treatment and outcome of ductal carcinoma in situ in the Netherlands.
    Breast Cancer Res Treat. 2021;187:245-254.
    PubMed         Abstract available
    
    
33. BYNG D, Retel VP, Schaapveld M, Wesseling J, et al
    Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?
    Breast Cancer Res Treat. 2021;187:187-196.
    PubMed         Abstract available
    
    
34. ZHANG Z, Chen X, Zhang J, Dai X, et al
    Cancer stem cell transcriptome landscape reveals biomarkers driving breast carcinoma heterogeneity.
    Breast Cancer Res Treat. 2021;186:89-98.
    PubMed         Abstract available
    
    
35. WU JM, Galibois AA, Seebocus N, Apu A, et al
    HER2 fluorescent in situ hybridization signal degradation: a 10-year retrospective study.
    Breast Cancer Res Treat. 2021;186:99-105.
    PubMed         Abstract available
    
    
36. HA SM, Chang JM, Kim SY, Lee SH, et al
    Prediction of axillary nodal burden in patients with invasive lobular carcinoma using MRI.
    Breast Cancer Res Treat. 2021;186:463-473.
    PubMed         Abstract available
    
    
37. SCHUMACHER K, Inciardi M, O'Neil M, Wagner JL, et al
    Is axillary imaging for invasive lobular carcinoma accurate in determining clinical node staging?
    Breast Cancer Res Treat. 2021;185:567-572.
    PubMed         Abstract available
    
    
38. HUANG CS, Lu TP, Liu CY, Huang CJ, et al
    Residual risk stratification of Taiwanese breast cancers following curative therapies with the extended concurrent genes signature.
    Breast Cancer Res Treat. 2021;186:475-485.
    PubMed         Abstract available
    
    
39. NARAYAN AK, Mercaldo SF, Gupta YP, Warner ET, et al
    Potential of using mammography screening appointments to identify high-risk women: cross sectional survey results from the national health interview survey.
    Breast Cancer Res Treat. 2021;186:229-235.
    PubMed         Abstract available
    
    
40. HALASZ SR, O'Keefe T, Wallace AM, Blair SL, et al
    Ductal carcinoma in situ in patients younger than 30 years: differences in adjuvant endocrine therapy and outcomes.
    Breast Cancer Res Treat. 2021;186:551-559.
    PubMed         Abstract available
    
    
41. RABAGLIO M, Sun Z, Maibach R, Giobbie-Hurder A, et al
    Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
    Breast Cancer Res Treat. 2021;185:697-707.
    PubMed         Abstract available
    
    
42. BAEK SY, Kim J, Chung IY, Ko BS, et al
    Long-term survival outcomes of repeat lumpectomy for ipsilateral breast tumor recurrence: a propensity score-matched analysis.
    Breast Cancer Res Treat. 2021;185:155-164.
    PubMed         Abstract available
    
    
43. TOUSSAINT A, Piaget-Rossel R, Stormacq C, Mathevet P, et al
    Width of margins in phyllodes tumors of the breast: the controversy drags on?-a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2021;185:21-37.
    PubMed         Abstract available
    
    
44. DENG J, Thennavan A, Shah S, Bagdatlioglu E, et al
    Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment.
    Breast Cancer Res Treat. 2021;185:85-94.
    PubMed         Abstract available
    
    
45. PONDE N, Agbor-Tarh D, Dal Lago L, Korde LA, et al
    Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).
    Breast Cancer Res Treat. 2021;185:107-116.
    PubMed         Abstract available
    
    
46. MANNLE H, Siebers JW, Momm F, Munstedt K, et al
    Impact of patients' refusal to undergo adjuvant treatment measures on survival.
    Breast Cancer Res Treat. 2021;185:239-246.
    PubMed         Abstract available
    
    
47. LLANOS AAM, Yao S, Singh A, Aremu JB, et al
    Gene expression of adipokines and adipokine receptors in the tumor microenvironment: associations of lower expression with more aggressive breast tumor features.
    Breast Cancer Res Treat. 2021;185:785-798.
    PubMed         Abstract available
    
    
48. LI X, Ma Z, Styblo TM, Arciero CA, et al
    Management of high-risk breast lesions diagnosed on core biopsies and experiences from prospective high-risk breast lesion conferences at an academic institution.
    Breast Cancer Res Treat. 2021;185:573-581.
    PubMed         Abstract available
    
    
49. RAPHAEL DANIELA DB, Russell NS, van Werkhoven E, Immink JM, et al
    Implementing a patient decision aid, a process evaluation of a large-scale pre- and post-implementation trial.
    Breast Cancer Res Treat. 2021;185:685-695.
    PubMed         Abstract available
    
    
50. ALIPOUR S
    Re: Naoum et al., Optimal breast reconstruction type for patients treated with neoadjuvant chemotherapy, mastectomy followed by radiation therapy.
    Breast Cancer Res Treat. 2021;185:885-886.
    PubMed        
    
    
51. GOMES R, Spinola PDS, Brant AC, Matta BP, et al
    Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.
    Breast Cancer Res Treat. 2021;185:851-861.
    PubMed         Abstract available
    
    
52. TARANTINO P, Prat A, Curigliano G
    New anti-HER2 agents for brain metastasis: histology-agnostic weapons?
    Breast Cancer Res Treat. 2021;185:879-881.
    PubMed         Abstract available
    
    
53. RASCHI E, Fusaroli M, Ardizzoni A, Poluzzi E, et al
    Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.
    Breast Cancer Res Treat. 2021;186:219-227.
    PubMed         Abstract available
    
    
54. SOMASUNDARAM SK, Potter S, Elgammal S, Maxwell AJ, et al
    Impalpable breast lesion localisation, a logistical challenge: results of the UK iBRA-NET national practice questionnaire.
    Breast Cancer Res Treat. 2021;185:13-20.
    PubMed         Abstract available
    
    
55. REYNA C, Johnston ME, Morris MC, Lee TC, et al
    National trends for axillary lymph node dissection and survival outcomes for clinical T3/T4 node-negative breast cancer patients undergoing mastectomy with positive lymph nodes.
    Breast Cancer Res Treat. 2021 Jun 18. pii: 10.1007/s10549-021-06290.
    PubMed         Abstract available
    
    
56. SALVIAT F, Charles C, Uzan C
    Shall patients' anxiety influence surgical decisions for atypical breast lesions? A substudy of the prospective NOMAT trial.
    Breast Cancer Res Treat. 2021;187:597-599.
    PubMed        
    
    
57. PATEL B, Merker L, Sahu A
    Letter to the editor regarding: 'Impalpable breast lesion localisation, a logistical challenge: results of the UK iBRA-NET national practice questionnaire'.
    Breast Cancer Res Treat. 2021;187:601-602.
    PubMed        
    
    
58. DEL VALLE DD, Pardo JA, Maselli AM, Valero MG, et al
    Evaluation of online Spanish and English health materials for preventive mastectomy. are we providing adequate information?
    Breast Cancer Res Treat. 2021;187:1-9.
    PubMed         Abstract available
    
    
59. HUANG S, Houssami N, Brennan M, Nickel B, et al
    The impact of mandatory mammographic breast density notification on supplemental screening practice in the United States: a systematic review.
    Breast Cancer Res Treat. 2021;187:11-30.
    PubMed         Abstract available
    
    
60. MCLEMORE LE, Albarracin CT, Gruschkus SK, Bassett RL Jr, et al
    HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines.
    Breast Cancer Res Treat. 2021;187:95-104.
    PubMed         Abstract available
    
    
61. TSANG JY, Lai ST, Ni YB, Shao Y, et al
    SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast.
    Breast Cancer Res Treat. 2021;187:339-347.
    PubMed         Abstract available
    
    
62. AUSTIN-DATTA RJ, Smotherman CR, Yaghjyan L
    Association between rice consumption and risk of cancer incidence in the California Teachers Study.
    Breast Cancer Res Treat. 2021;187:917-918.
    PubMed        
    
    
63. GAO Y, Wu N, Wang S, Yang X, et al
    Concurrent mutations associated with trastuzumab-resistance revealed by single cell sequencing.
    Breast Cancer Res Treat. 2021;187:613-624.
    PubMed         Abstract available
    
    
64. SWARNKAR PK, Mokbel K
    Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy.
    Breast Cancer Res Treat. 2021;187:919-920.
    PubMed        
    
    
65. FEGHHI M, Rezaie J, Mostafanezhad K, Jabbari N, et al
    Bystander effects induced by electron beam-irradiated MCF-7 cells: a potential mechanism of therapy resistance.
    Breast Cancer Res Treat. 2021;187:657-671.
    PubMed         Abstract available
    
    
66. MORENO G, Molina M, Wu R, Sullivan JR, et al
    Unveiling the histopathologic spectrum of MRI-guided breast biopsies: an institutional pathological-radiological correlation.
    Breast Cancer Res Treat. 2021;187:673-680.
    PubMed         Abstract available
    
    
67. BALIJA TM, Braz D, Hyman S, Montgomery LL, et al
    Early reflector localization improves the accuracy of localization and excision of a previously positive axillary lymph node following neoadjuvant chemotherapy in patients with breast cancer.
    Breast Cancer Res Treat. 2021 Jun 23. pii: 10.1007/s10549-021-06281.
    PubMed         Abstract available
    
    
68. COLE KM, Clemons M, Alzahrani M, Larocque G, et al
    Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers.
    Breast Cancer Res Treat. 2021 Jun 22. pii: 10.1007/s10549-021-06186.
    PubMed         Abstract available
    
    
69. KO G, Hota S, Cil TD
    COVID-19 vaccination and breast cancer surgery timing.
    Breast Cancer Res Treat. 2021 Jun 22. pii: 10.1007/s10549-021-06293.
    PubMed         Abstract available
    
    
70. KIM H, Kim YJ, Park D, Park WY, et al
    Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.
    Breast Cancer Res Treat. 2021 Jun 21. pii: 10.1007/s10549-021-06296.
    PubMed         Abstract available
    
    
71. STEBBING J, Baranau YV, Baryash V, Manikhas A, et al
    Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.
    Breast Cancer Res Treat. 2021 Jun 20. pii: 10.1007/s10549-021-06240.
    PubMed         Abstract available
    
    
72. PAWLOSKI KR, Tadros AB, Sevilimedu V, Newman A, et al
    Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy.
    Breast Cancer Res Treat. 2021;186:617-624.
    PubMed         Abstract available
    
    
73. KOJIMAHARA T, Kageyama T
    Octopus anastomosis: selection of anastomotic configuration in lymphaticovenular anastomosis according to vessels' conditions.
    Breast Cancer Res Treat. 2021;186:887-888.
    PubMed        
    
    
74. LO GULLO R, Vincenti K, Rossi Saccarelli C, Gibbs P, et al
    Diagnostic value of radiomics and machine learning with dynamic contrast-enhanced magnetic resonance imaging for patients with atypical ductal hyperplasia in predicting malignant upgrade.
    Breast Cancer Res Treat. 2021;187:535-545.
    PubMed         Abstract available
    
    
75. YANG C, Arnold AG, Catchings A, Rai V, et al
    The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer.
    Breast Cancer Res Treat. 2021;185:869-877.
    PubMed         Abstract available
    
    
76. SHANI H, Bernstein-Molho R, Laitman Y, Netzer I, et al
    Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations.
    Breast Cancer Res Treat. 2021;186:259-263.
    PubMed         Abstract available
    
    
77. VAN DEN BRUELE AB, Chen I, Sevilimedu V, Le T, et al
    Management of ipsilateral breast tumor recurrence following breast conservation surgery: a comparative study of re-conservation vs mastectomy.
    Breast Cancer Res Treat. 2021;187:105-112.
    PubMed         Abstract available
    
    
78. ALANKO J, Tanner M, Vanninen R, Auvinen A, et al
    Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis.
    Breast Cancer Res Treat. 2021;187:267-274.
    PubMed         Abstract available
    
    
79. THEBERGE I, Vandal N, Perron L, Guertin MH, et al
    Association between radiologists' and facilities' characteristics and mammography screening detection of ductal carcinoma in situ.
    Breast Cancer Res Treat. 2021;187:255-266.
    PubMed         Abstract available
    
    
80. GUI G, Panopoulou E, Tang S, Twelves D, et al
    The INTEND 1 randomized controlled trial of duct endoscopy as an indicator of margin excision in breast conservation surgery.
    Breast Cancer Res Treat. 2021;186:723-730.
    PubMed         Abstract available
    
    
81. FILIPE MD, Patuleia SIS, Vriens MR, van Diest PJ, et al
    Meta-analysis and cost-effectiveness of ductoscopy, duct excision surgery and MRI for the diagnosis and treatment of patients with pathological nipple discharge.
    Breast Cancer Res Treat. 2021;186:285-293.
    PubMed         Abstract available
    
    
82. ALDOSARY G, Caudrelier JM, Arnaout A, Chang L, et al
    Can we rely on surgical clips placed during oncoplastic breast surgery to accurately delineate the tumor bed for targeted breast radiotherapy?
    Breast Cancer Res Treat. 2021;186:343-352.
    PubMed         Abstract available
    
    
83. ZHI WI, Baser RE, Kwon A, Chen C, et al
    Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing.
    Breast Cancer Res Treat. 2021;186:761-768.
    PubMed         Abstract available
    
    
84. STOEN E, Kagihara J, Shagisultanova E, Fisher CM, et al
    Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval.
    Breast Cancer Res Treat. 2021;187:883-891.
    PubMed         Abstract available
    
    
85. LANCETA L, Lypova N, O'Neill C, Li X, et al
    Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq.
    Breast Cancer Res Treat. 2021;186:677-686.
    PubMed         Abstract available
    
    
86. JIAGGE EM, Ulintz PJ, Wong S, McDermott SP, et al
    Multiethnic PDX models predict a possible immune signature associated with TNBC of African ancestry.
    Breast Cancer Res Treat. 2021;186:391-401.
    PubMed         Abstract available
    
    
87. PARKES A, Wang WL, Patel S, Leung CH, et al
    Outcomes of systemic therapy in metastatic phyllodes tumor of the breast.
    Breast Cancer Res Treat. 2021;186:871-882.
    PubMed         Abstract available
    
    
88. GRILL S, Yahiaoui-Doktor M, Basrai M, Struck J, et al
    Precursor fractions of neurotensin and enkephalin might point to molecular mechanisms of cancer risk modulation during a lifestyle-intervention in germline BRCA1/2 gene mutation carriers.
    Breast Cancer Res Treat. 2021;186:741-752.
    PubMed         Abstract available
    
    
89. YANG L, Roy M, Lin H, Shen Y, et al
    Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast.
    Breast Cancer Res Treat. 2021;186:403-415.
    PubMed         Abstract available
    
    
90. RAFN BS, Christensen J, Bloomquist K
    Letter to the editor re: Shah et al.: "The impact of monitoring techniques on progression to chronic breast cancerrelated lymphedema: a metaanalysis comparing bioimpedance spectroscopy versus circumferential measurements".
    Breast Cancer Res Treat. 2021;186:269-270.
    PubMed        
    
    

    
    Breast J

91. KUSHVAHA S, Mehta S, Rajan F, R S, et al
    All the lumps are primarily not from breast-report of a metastatic breast lump in a cervical cancer survivor.
    Breast J. 2020 May 7. doi: 10.1111/tbj.13869.
    PubMed        
    
    
92. STRUIK GM, Schermers B, Mares I, Lont HE, et al
    Randomized controlled trial comparing magnetic marker localization (MaMaLoc) with wire-guided localization in the treatment of early-stage breast cancer.
    Breast J. 2021 Jun 17. doi: 10.1111/tbj.14262.
    PubMed         Abstract available
    
    
93. MASOOD S
    This is Not Only about the Biology: The Socioeconomic Disparities among African American Women with Breast Cancer Still Play a Significant Role.
    Breast J. 2021 Jun 18. doi: 10.1111/tbj.14263.
    PubMed        
    
    

    
    Cancer

94. MAKHNOON S, Tran G, Levin B, Mattie KD, et al
    Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes.
    Cancer. 2021 Jun 22. doi: 10.1002/cncr.33668.
    PubMed         Abstract available
    
    
95. LYNCE F, Blackburn MJ, Zhuo R, Gallagher C, et al
    Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer.
    Cancer. 2021 Jun 22. doi: 10.1002/cncr.33620.
    PubMed         Abstract available
    
    
96. RENTSCHER KE, Zhao X, Small BJ, Cohen HJ, et al
    Loneliness and mental health during the COVID-19 pandemic in older breast cancer survivors and noncancer controls.
    Cancer. 2021 Jun 23. doi: 10.1002/cncr.33687.
    PubMed         Abstract available
    
    
97. BROWN JC, Sarwer DB, Troxel AB, Sturgeon K, et al
    A randomized trial of exercise and diet on health-related quality of life in survivors of breast cancer with overweight or obesity.
    Cancer. 2021 Jun 23. doi: 10.1002/cncr.33752.
    PubMed         Abstract available
    
    
98. GREER AC, Lanes A, Poorvu PD, Kennedy P, et al
    The impact of fertility preservation on the timing of breast cancer treatment, recurrence, and survival.
    Cancer. 2021 Jun 23. doi: 10.1002/cncr.33601.
    PubMed         Abstract available
    
    

    
    Cancer Cell

99. PUSZTAI L, Yau C, Wolf DM, Han HS, et al
    Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
    Cancer Cell. 2021 Jun 2. pii: S1535-6108(21)00275.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

100. HUA J, Zhang Z, Zhang L, Sun Y, et al
     UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells.
     Cancer Chemother Pharmacol. 2021 Jun 19. pii: 10.1007/s00280-021-04303.
     PubMed         Abstract available
     
     

     
     Cancer Lett

101. SANG X, Li L, Rui C, Liu Y, et al
     Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer.
     Cancer Lett. 2021;518:82-93.
     PubMed         Abstract available
     
     

     
     Cancer Res

102. CANO A, Lopez-Menendez C, Vazquez-Naharro A, Santos V, et al
     E2A modulates stemness, metastasis, and therapeutic resistance of breast cancer.
     Cancer Res. 2021 Jun 18. pii: 0008-5472.CAN-20-2685.
     PubMed         Abstract available
     
     
103. PRODHOMME MK, Pommier RM, Franchet C, Fauvet F, et al
     EMT Transcription Factor ZEB1 Represses the Mutagenic POLtheta-Mediated End-Joining Pathway in Breast Cancers.
     Cancer Res. 2021;81:1595-1606.
     PubMed         Abstract available
     
     
104. LAINE A, Nagelli SG, Farrington C, Butt U, et al
     CIP2A interacts with TopBP1 and drives basal-like breast cancer tumorigenesis.
     Cancer Res. 2021 Jun 18. pii: 0008-5472.CAN-20-3651.
     PubMed         Abstract available
     
     
105. SHARIF GM, Campbell MJ, Nasir A, Sengupta S, et al
     An AIB1 isoform alters enhancer access and enables progression of early stage triple-negative breast cancer.
     Cancer Res. 2021 Jun 16. pii: 0008-5472.CAN-20-3625.
     PubMed         Abstract available
     
     

     
     Clin Breast Cancer

106. ANAND K, Niravath P, Patel T, Ensor J, et al
     A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer.
     Clin Breast Cancer. 2021;21:199-204.
     PubMed         Abstract available
     
     
107. BORTOLOZO HI, Derchain S, Vechin FC, Maginador GF, et al
     Aerobic Fitness is a Predictor of Body Composition in Women With Breast Cancer at Diagnosis.
     Clin Breast Cancer. 2021;21:e245-e251.
     PubMed         Abstract available
     
     
108. SYMONDS L, Jenkins I, Linden HM, Kurland B, et al
     A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Ca
     Clin Breast Cancer. 2021 May 24. pii: S1526-8209(21)00137.
     PubMed         Abstract available
     
     
109. GUILLERM SO, Bourstyn E, Itti R, Cahen-Doidy L, et al
     Intraoperative Radiotherapy for Breast Cancer in Elderly Women.
     Clin Breast Cancer. 2021 May 15. pii: S1526-8209(21)00130.
     PubMed         Abstract available
     
     
110. MEYER C, Bailleux C, Chamorey E, Schiappa R, et al
     Factors Involved in Delaying Initiation of Adjuvant Chemotherapy After Breast Cancer Surgery.
     Clin Breast Cancer. 2021 May 24. pii: S1526-8209(21)00135.
     PubMed         Abstract available
     
     
111. HAMILTON EP, Kaklamani V, Falkson C, Vidal GA, et al
     Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
     Clin Breast Cancer. 2021 May 15. pii: S1526-8209(21)00089.
     PubMed         Abstract available
     
     
112. DENG C, Xie Y, Liu Y, Li Y, et al
     Aromatherapy Plus Music Therapy Improve Pain Intensity and Anxiety Scores in Patients With Breast Cancer During Perioperative Periods: A Randomized Controlled Trial.
     Clin Breast Cancer. 2021 May 20. pii: S1526-8209(21)00134.
     PubMed         Abstract available
     
     

     
     Eur J Cancer

113. O'SHAUGHNESSY J, Sousa S, Cruz J, Fallowfield L, et al
     Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
     Eur J Cancer. 2021;152:223-232.
     PubMed         Abstract available
     
     
114. GUARNERI V, Dieci MV, Griguolo G, Miglietta F, et al
     Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial.
     Eur J Cancer. 2021;153:133-141.
     PubMed         Abstract available
     
     

     
     Eur Radiol

115. JIN L, Wang R, Zhuang L, Jin Y, et al
     Evaluation of whole axillary status with lymphatic contrast-enhanced ultrasound in patients with breast cancer.
     Eur Radiol. 2021 Jun 24. pii: 10.1007/s00330-021-08100.
     PubMed         Abstract available
     
     
116. POSSO M, Alcantara R, Vazquez I, Comerma L, et al
     Mammographic features of benign breast lesions and risk of subsequent breast cancer in women attending breast cancer screening.
     Eur Radiol. 2021 Jun 22. pii: 10.1007/s00330-021-08118.
     PubMed         Abstract available
     
     
117. BOITA J, van Engen RE, Mackenzie A, Tingberg A, et al
     How does image quality affect radiologists' perceived ability for image interpretation and lesion detection in digital mammography?
     Eur Radiol. 2021;31:5335-5343.
     PubMed         Abstract available
     
     
118. LAMBERT J, Steelandt T, Heywang-Kobrunner SH, Gieraerts K, et al
     Long-term MRI-guided vacuum-assisted breast biopsy results of 600 single-center procedures.
     Eur Radiol. 2021;31:4886-4897.
     PubMed         Abstract available
     
     
119. PERRE SV, Duron L, Milon A, Bekhouche A, et al
     Radiomic analysis of HTR-DCE MR sequences improves diagnostic performance compared to BI-RADS analysis of breast MR lesions.
     Eur Radiol. 2021;31:4848-4859.
     PubMed         Abstract available
     
     
120. DONG F, She R, Cui C, Shi S, et al
     One step further into the blackbox: a pilot study of how to build more confidence around an AI-based decision system of breast nodule assessment in 2D ultrasound.
     Eur Radiol. 2021;31:4991-5000.
     PubMed         Abstract available
     
     

     
     Exp Cell Res

121. ZHU B, Zhang X, Sun S, Fu Y, et al
     NF-kappaB and neutrophil extracellular traps cooperate to promote breast cancer progression and metastasis.
     Exp Cell Res. 2021;405:112707.
     PubMed         Abstract available
     
     

     
     Int J Cancer

122. BUDUKH A, Dikshit R, Chaturvedi P
     Outcome of the randomized control screening trials on Oral, Cervix and Breast Cancer from India and way forward in COVID-19 pandemic situation.
     Int J Cancer. 2021 Jun 21. doi: 10.1002/ijc.33712.
     PubMed        
     
     
123. HEIDRICH I, Ackar L, Mossahebi Mohammadi P, Pantel K, et al
     Liquid biopsies: Potential and challenges.
     Int J Cancer. 2021;148:528-545.
     PubMed         Abstract available
     
     

     
     Int J Radiat Oncol Biol Phys

124. TOM MC, Sittenfeld SMC, Shah C, Bauer-Nilsen K, et al
     Use of a Radiation Tumor Bed Boost After Breast-Conserving Surgery and Whole-Breast Irradiation: Time Trends and Correlates.
     Int J Radiat Oncol Biol Phys. 2021;109:273-280.
     PubMed         Abstract available
     
     

     
     J Natl Cancer Inst

125. PIMENTEL I, Chen BE, Lohmann AE, Ennis M, et al
     The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32.
     J Natl Cancer Inst. 2021;113:192-198.
     PubMed         Abstract available
     
     
126. FARBER R, Houssami N, Wortley S, Jacklyn G, et al
     Impact of Full-Field Digital Mammography Versus Film-Screen Mammography in Population Screening: A Meta-Analysis.
     J Natl Cancer Inst. 2021;113:16-26.
     PubMed         Abstract available
     
     
127. BRAWLEY OW, Paller CJ
     Overdiagnosis in the Age of Digital Cancer Screening.
     J Natl Cancer Inst. 2021;113:1-2.
     PubMed        
     
     

     
     J Surg Oncol

128. KOCA B, Yildirim M
     Delay in breast cancer diagnosis and its clinical consequences during the coronavirus disease pandemic.
     J Surg Oncol. 2021 Jun 17. doi: 10.1002/jso.26581.
     PubMed         Abstract available
     
     

     
     Lancet Oncol

129. GRINDA T, Delaloge S
     BRCA2: a 25-year journey from gene identification to targeted cancer treatment.
     Lancet Oncol. 2021;22:763-764.
     PubMed        
     
     

     
     NPJ Breast Cancer

130. ZHUANG Y, Grainger JM, Vedell PT, Yu J, et al
     Establishment and characterization of immortalized human breast cancer cell lines from breast cancer patient-derived xenografts (PDX).
     NPJ Breast Cancer. 2021;7:79.
     PubMed         Abstract available
     
     
131. JOHNSTON S, O'Shaughnessy J, Martin M, Huober J, et al
     Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups.
     NPJ Breast Cancer. 2021;7:80.
     PubMed         Abstract available
     
     
132. KEANE H, Huilgol YS, Shieh Y, Tice JA, et al
     Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial.
     NPJ Breast Cancer. 2021;7:78.
     PubMed         Abstract available
     
     

     
     Oncogene

133. BI X, Lou P, Song Y, Sheng X, et al
     Msi1 promotes breast cancer metastasis by regulating invadopodia-mediated extracellular matrix degradation via the Timp3-Mmp9 pathway.
     Oncogene. 2021 Jun 21. pii: 10.1038/s41388-021-01873.
     PubMed         Abstract available
     
     

     
     Oncology (Williston Park)

134. MILES R, Nicolae A, Ravi A
     Routine Breast Cancer Screening in Average-Risk Women Younger Than 50 Years: Current Paradigms Based on National Guidelines.
     Oncology (Williston Park). 2021;:6.
     PubMed         Abstract available
     
     

     
     PLoS Comput Biol

135. TRENTHAM-DIETZ A, Alagoz O, Chapman C, Huang X, et al
     Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts.
     PLoS Comput Biol. 2021;17:e1009020.
     PubMed         Abstract available
     
     
136. SUSAK H, Serra-Saurina L, Demidov G, Rabionet R, et al
     Efficient and flexible Integration of variant characteristics in rare variant association studies using integrated nested Laplace approximation.
     PLoS Comput Biol. 2021;17:e1007784.
     PubMed         Abstract available
     
     

     
     PLoS One

137. VIVES N, Farre A, Ibanez-Sanz G, Vidal C, et al
     Text messaging as a tool to improve cancer screening programs (M-TICS Study): A randomized controlled trial protocol.
     PLoS One. 2021;16:e0245806.
     PubMed         Abstract available
     
     
138. WIELEMA M, Sijens PE, Dijkstra H, De Bock GH, et al
     Diffusion weighted imaging of the breast: Performance of standardized breast tumor tissue selection methods in clinical decision making.
     PLoS One. 2021;16:e0245930.
     PubMed         Abstract available
     
     
139. SALAS M, Henderson M, Sundararajan M, Tu N, et al
     Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review.
     PLoS One. 2021;16:e0252925.
     PubMed         Abstract available
     
     
140. HSU SN, Hui EWE, Liu M, Wu D, et al
     Revealing nuclear receptor hub modules from Basal-like breast cancer expression networks.
     PLoS One. 2021;16:e0252901.
     PubMed         Abstract available
     
     
141. OSEI-AFRIYIE S, Addae AK, Oppong S, Amu H, et al
     Breast cancer awareness, risk factors and screening practices among future health professionals in Ghana: A cross-sectional study.
     PLoS One. 2021;16:e0253373.
     PubMed         Abstract available
     
     
142. ALMUHTASEB MIA, Alby F, Zucchermaglio C, Fatigante M, et al
     Social support for breast cancer patients in the occupied Palestinian territory.
     PLoS One. 2021;16:e0252608.
     PubMed         Abstract available
     
     

     
     Pol J Radiol

143. YADAV P, Harit S, Kumar D
     Efficacy of high-resolution, 3-D diffusion-weighted imaging in the detection of breast cancer compared to dynamic contrast-enhanced magnetic resonance imaging.
     Pol J Radiol. 2021;86:e277-e286.
     PubMed         Abstract available
     
     
144. YETKIN DI, Akpinar MG, Durhan G, Demirkazik FB, et al
     Comparison of clinical and magnetic resonance imaging findings of triple-negative breast cancer with non-triple-negative tumours.
     Pol J Radiol. 2021;86:e269-e276.
     PubMed         Abstract available
     
     

     
     Proc Natl Acad Sci U S A

145. JIMENEZ-SANCHEZ J, Bosque JJ, Jimenez Londono GA, Molina-Garcia D, et al
     Evolutionary dynamics at the tumor edge reveal metabolic imaging biomarkers.
     Proc Natl Acad Sci U S A. 2021;118.
     PubMed         Abstract available
     
     

     
     Radiother Oncol

146. MATTEO LUCA BATTISTI N, Hatton MQ, Wr Reed M, Herbert E, et al
     Observational cohort study in older women with early breast cancer: use of radiation therapy and impact on health-related quality of life and mortality.
     Radiother Oncol. 2021 Jun 16. pii: S0167-8140(21)06593.
     PubMed         Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: